MX2014014021A - Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido. - Google Patents

Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido.

Info

Publication number
MX2014014021A
MX2014014021A MX2014014021A MX2014014021A MX2014014021A MX 2014014021 A MX2014014021 A MX 2014014021A MX 2014014021 A MX2014014021 A MX 2014014021A MX 2014014021 A MX2014014021 A MX 2014014021A MX 2014014021 A MX2014014021 A MX 2014014021A
Authority
MX
Mexico
Prior art keywords
methods
chelate complex
polypeptide compositions
oligonucleotide chelate
polypeptide
Prior art date
Application number
MX2014014021A
Other languages
English (en)
Other versions
MX346239B (es
Inventor
Andrew Vaillant
Michel Bazinet
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014014021(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of MX2014014021A publication Critical patent/MX2014014021A/es
Publication of MX346239B publication Critical patent/MX346239B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describe una composición farmacéutica que contiene un complejo de quelato de oligonucleótido y al menos un polipéptido o polipéptido pegilado. La presente descripción también describe composiciones farmacéuticas adicionales y métodos para el tratamiento de enfermedades que incluyen infecciones virales.
MX2014014021A 2012-05-18 2013-05-17 Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido. MX346239B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (2)

Publication Number Publication Date
MX2014014021A true MX2014014021A (es) 2015-02-10
MX346239B MX346239B (es) 2017-03-13

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014021A MX346239B (es) 2012-05-18 2013-05-17 Composiciones y metodos de polipeptidos-complejo de quelato de oligonucleotido.

Country Status (34)

Country Link
US (1) US9492506B2 (es)
EP (1) EP2849798B1 (es)
JP (1) JP2015517504A (es)
KR (1) KR102068109B1 (es)
CN (1) CN104349793B (es)
AU (1) AU2013262416B2 (es)
BR (1) BR112014028654A2 (es)
CA (1) CA2873529C (es)
CL (1) CL2014003134A1 (es)
CO (1) CO7131387A2 (es)
CR (1) CR20140527A (es)
CY (1) CY1124345T1 (es)
DK (1) DK2849798T3 (es)
DO (1) DOP2014000264A (es)
EA (1) EA035967B1 (es)
EC (1) ECSP14027694A (es)
ES (1) ES2873844T3 (es)
HK (1) HK1204279A1 (es)
HR (1) HRP20210840T1 (es)
HU (1) HUE054875T2 (es)
IL (1) IL235548B (es)
LT (1) LT2849798T (es)
MX (1) MX346239B (es)
MY (1) MY168778A (es)
NZ (1) NZ703095A (es)
PH (1) PH12014502551B1 (es)
PL (1) PL2849798T3 (es)
PT (1) PT2849798T (es)
RS (1) RS62030B1 (es)
SG (1) SG11201407599SA (es)
SI (1) SI2849798T1 (es)
TW (1) TWI635864B (es)
WO (1) WO2013170386A1 (es)
ZA (1) ZA201408674B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141308A2 (en) 2007-05-11 2008-11-20 Adynxx, Inc. Gene expression and pain
JP6251247B2 (ja) 2012-05-10 2017-12-20 エーダイニクス インコーポレイテッド 活性成分の送達のための製剤
MX361522B (es) 2012-08-30 2018-12-10 Replicor Inc Uso de agentes farmacéuticos para la preparacion de un medicamento para el tratamiento de hepatitis b y hepatitis d.
HRP20231400T1 (hr) 2014-07-10 2024-02-16 Replicor Inc. Kelirani fosforotioirani polimeri nukleinskih kiselina, namijenjeni upotrebi u kombinaciji s inhibitorom hbv polimeraze u liječenju infekcija virusima hepatitisa b i hepatitisa d
PT3180434T (pt) 2014-08-15 2019-10-29 Adynxx Inc Chamarizes oligonucleotídicos para o tratamento da dor
AU2019376079A1 (en) * 2018-11-08 2021-05-27 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
BR0314236A (pt) * 2002-09-13 2005-08-09 Replicor Inc Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
JP2006519235A (ja) * 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
RU2006118359A (ru) * 2003-10-27 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Комбинации для лечения вирусного гепатита с (hcv)
AU2005297376A1 (en) * 2004-10-19 2006-04-27 Replicor Inc. Antiviral oligonucleotides
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
US20090215873A1 (en) * 2005-09-29 2009-08-27 Andrew Vaillant Therapeutic Molecules and their Uses
US7776818B2 (en) * 2005-09-29 2010-08-17 S-Cell Biosciences, Inc. Methods to treat T-cell disorders using TISF
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
US20090238772A1 (en) 2007-12-13 2009-09-24 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
ES2651308T3 (es) * 2009-10-16 2018-01-25 Glaxo Group Limited Inhibidores antisentido de HBV
PL2605794T3 (pl) * 2010-08-20 2017-01-31 Replicor Inc. Chelatowe kompleksy oligonukleotydów
MX361522B (es) 2012-08-30 2018-12-10 Replicor Inc Uso de agentes farmacéuticos para la preparacion de un medicamento para el tratamiento de hepatitis b y hepatitis d.

Also Published As

Publication number Publication date
US9492506B2 (en) 2016-11-15
EP2849798A1 (en) 2015-03-25
CY1124345T1 (el) 2022-07-22
EA035967B1 (ru) 2020-09-07
PH12014502551A1 (en) 2015-01-21
WO2013170386A1 (en) 2013-11-21
EA201401278A1 (ru) 2015-04-30
KR102068109B1 (ko) 2020-01-21
ECSP14027694A (es) 2015-12-31
HUE054875T2 (hu) 2021-10-28
CN104349793B (zh) 2017-11-10
DK2849798T3 (da) 2021-05-31
CO7131387A2 (es) 2014-12-01
CL2014003134A1 (es) 2015-02-13
JP2015517504A (ja) 2015-06-22
EP2849798A4 (en) 2016-03-09
PL2849798T3 (pl) 2021-10-18
ZA201408674B (en) 2016-01-27
PH12014502551B1 (en) 2015-01-21
ES2873844T3 (es) 2021-11-04
SI2849798T1 (sl) 2021-08-31
AU2013262416A1 (en) 2014-12-18
MY168778A (en) 2018-12-04
HRP20210840T1 (hr) 2021-08-06
RS62030B1 (sr) 2021-07-30
SG11201407599SA (en) 2014-12-30
CN104349793A (zh) 2015-02-11
AU2013262416B2 (en) 2017-05-11
TW201408308A (zh) 2014-03-01
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
HK1204279A1 (en) 2015-11-13
EP2849798B1 (en) 2021-04-07
MX346239B (es) 2017-03-13
IL235548B (en) 2019-07-31
NZ703095A (en) 2016-07-29
CA2873529C (en) 2020-08-18
PT2849798T (pt) 2021-05-18
TWI635864B (zh) 2018-09-21
US20130309201A1 (en) 2013-11-21
CR20140527A (es) 2014-12-15
LT2849798T (lt) 2021-08-10
DOP2014000264A (es) 2015-01-31
CA2873529A1 (en) 2013-11-21
KR20150013309A (ko) 2015-02-04

Similar Documents

Publication Publication Date Title
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
IN2015DN01156A (es)
PH12014502551B1 (en) Oligonucleotide chelate complex-polypeptide compositions and methods
TN2015000278A1 (en) Autotaxin inhibitors
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
EP2872151A4 (en) ACELLULAR PRO-TOLEROGENIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
JO3357B1 (ar) مركبات إيميدازوبيروليدينون
MY172292A (en) Vectors and sequences for the treatment of diseases
PH12015500724A1 (en) 1, 2, 4-triazine derivatives for the treatment of viral infections
MX349004B (es) Nuevos compuestos.
MX2015011193A (es) Compuestos antivirales.
IN2014CN00572A (es)
MX2015011198A (es) Compuestos antivirales.
MX2015010892A (es) Compuestos antivirales.
MX2015011125A (es) Compuestos antivirales.
MX2015011126A (es) Compuestos antivirales.
IN2014DN10683A (es)
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
GB201114923D0 (en) Immunogenic proteins and compositions
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses

Legal Events

Date Code Title Description
FG Grant or registration